The percentage of children and adolescents affected by obesity has more than tripled since the 1970s, according to the CDC; nearly 1 in 5 American youth are obese. According to data from the National Health and Nutrition Examination Survey, around 18% of youth ages 2 to 19 years were obese and nearly 6% were severely obese in 2015-2016. Rates of obesity and severe obesity in adolescents (ages 12 to 19 years) are even higher.Read More
The Food and Drug Administration (FDA) last week approved Epidiolex (cannabidiol; GW Pharmaceuticals) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana; it’s also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.Read More
Innovative medical treatments are being developed at an astonishing pace. However, rising medical costs are a roadblock to patient access to many of these innovations. Last month, Secretary of Health and Human Services Alex Azar rolled out a blueprint to address this challenge. The blueprint highlights the importance of linking payments for medical treatments to their value and removing regulatory obstacles to value-based purchasing.Read More
Recently, the FDA approved Palynziq (pegvaliase-pqpz; BioMarin Pharmaceutical Inc.), a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations on existing management.Read More
With the promise of shorter hospital stays, less blood loss, less pain, fewer complications from surgery, and a quicker return to normal activities for most patients, many hospitals and healthcare systems are embracing the use of robotic surgery systems.Read More
The FDA has approved Doptelet (avatrombopag; AkaRx Inc.), a drug used for the treatment of thrombocytopenia in adult patients with chronic liver disease who have low blood platelets and are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use.Read More
Hayes is a company of real people. We’d like you to get to know us and the ways we strive to provide personalized service to you, our clients. This month, let us introduce you to another valuable contributor to the Hayes mission of providing fiercely-unbiased evidence, and our product owner of client-led product innovation. Meet Marco Angeli.Read More
Hayes is a company of real people and we’d like you to get to know us. This month, we introduce you to another valuable contributor to the Hayes mission of providing fiercely unbiased evidence. Meet Beth Bontemps.
Ms. Bontemps joined Hayes in September 2014 as a Senior Analyst. In 2017, she was promoted to the position of Product Manager, Prognosis and News Service.
She comes to Hayes from JR Associates Inc., a medical technology reimbursement consulting firm where she worked as a clinical and reimbursement consultant.Read More
Topics: Hayes Blog